中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
13期
119-120
,共2页
红霉素%阿奇霉素%小儿%支原体肺炎
紅黴素%阿奇黴素%小兒%支原體肺炎
홍매소%아기매소%소인%지원체폐염
Erythromycin%Azithromycin%Children patients%Mycoplasma pneumonia
目的:分析红霉素联合阿奇霉素治疗小儿支原体肺炎的临床效果。方法搜集本院儿科诊治的2014年2月~2015年1月期间的43例小儿支原体肺炎患儿,按照随机数表法分为两组,研究组23例采用红霉素联合阿奇霉素,对照组20例采用单纯阿奇霉素,对比治疗效果。结果两组比较,研究组患儿痊愈率78.3%、治疗总好转率为95.7%,高于对照组的50.0%、85.0%;不良反应比较,研究组的发生率8.7%,低于对照组的20.0%(P<0.05)。结论红霉素与阿奇霉素联合治疗小儿支原体肺炎的效果显著,患儿的痊愈率高、治疗总好转率高,且不良反应的发生率低。
目的:分析紅黴素聯閤阿奇黴素治療小兒支原體肺炎的臨床效果。方法搜集本院兒科診治的2014年2月~2015年1月期間的43例小兒支原體肺炎患兒,按照隨機數錶法分為兩組,研究組23例採用紅黴素聯閤阿奇黴素,對照組20例採用單純阿奇黴素,對比治療效果。結果兩組比較,研究組患兒痊愈率78.3%、治療總好轉率為95.7%,高于對照組的50.0%、85.0%;不良反應比較,研究組的髮生率8.7%,低于對照組的20.0%(P<0.05)。結論紅黴素與阿奇黴素聯閤治療小兒支原體肺炎的效果顯著,患兒的痊愈率高、治療總好轉率高,且不良反應的髮生率低。
목적:분석홍매소연합아기매소치료소인지원체폐염적림상효과。방법수집본원인과진치적2014년2월~2015년1월기간적43례소인지원체폐염환인,안조수궤수표법분위량조,연구조23례채용홍매소연합아기매소,대조조20례채용단순아기매소,대비치료효과。결과량조비교,연구조환인전유솔78.3%、치료총호전솔위95.7%,고우대조조적50.0%、85.0%;불량반응비교,연구조적발생솔8.7%,저우대조조적20.0%(P<0.05)。결론홍매소여아기매소연합치료소인지원체폐염적효과현저,환인적전유솔고、치료총호전솔고,차불량반응적발생솔저。
Objective To study clinical ef ect of Erythromycin combined with Azithromycin in treatment of mycoplasma pneumonia in children. Methods 43 children patients with mycoplasma pneumonia were chose in our hospital from February 2014 to January 2015 and the patients were divided into two groups according to random number table. There were 23 patients in study group who were given Erythromycin combined with Azithromycin medication treatment. There were 20 patients in control group who were given Azithromycin medication treatment only. Treatment ef ects were compared between two groups after treatment. Results The recovery rate and improvement rate of study group were 78.3%and 95.7%which were much higher than that were 50.0%and 85.0%in control group. The rate of adverse ef ects was 8.7%in study group which was much lower than that was 20%in control group(P<0.05). Conclusion The ef ect of erythromycin combined with azithromycin medication is prominent in treatment of children patients with mycoplasma pneumonia. It is conducive to increasing recovery rate and improvement rate of children patients and reducing rate of adverse ef ects.